| Drug Name |
Atovaquone |
| Drug ID |
BADD_D00186 |
| Description |
Atovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols. |
| Indications and Usage |
For the treatment or prevention of Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMX). Also indicated for the acute oral treatment of mild to moderate PCP in patients who are intolerant to TMP-SMX. |
| Marketing Status |
approved |
| ATC Code |
P01AX06 |
| DrugBank ID |
DB01117
|
| KEGG ID |
D00236
|
| MeSH ID |
D053626
|
| PubChem ID |
74989
|
| TTD Drug ID |
D06ZEE
|
| NDC Product Code |
0904-7064; 62147-0058; 0121-1796; 68462-421; 58159-048; 65977-0034; 51552-1629; 0173-0547; 62135-528; 65162-693; 69452-252; 70748-299; 65015-734; 59651-090; 63827-1005; 71052-261; 16714-900; 31722-629; 51407-642; 10702-223; 0121-0898; 60687-534; 66039-840; 0173-0665; 62147-0057; 66039-928; 66689-062; 62331-059; 50268-086 |
| UNII |
Y883P1Z2LT
|
| Synonyms |
Atovaquone | 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone | 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone | Wellvone | Mepron | 566C | compound 566 | 566C80 | hydroxynaphthoquinone 566C80 | 566C80 hydroxynaphthoquinone | hydroxynaphthoquinone, 566C80 |
